MP56-09 EXPRESSION PROFILE OF CD44S, CD44V6, AND CD44V10 IN LOCALIZED PROSTATE CANCER: IMPACT ON PROGNOSTIC OUTCOMES FOLLOWING RADICAL PROSTATECTOMY

Abstract

You have accessJournal of UrologyProstate Cancer: Localized III1 Apr 2015MP56-09 EXPRESSION PROFILE OF CD44S, CD44V6, AND CD44V10 IN LOCALIZED PROSTATE CANCER: IMPACT ON PROGNOSTIC OUTCOMES FOLLOWING RADICAL PROSTATECTOMY Hiromoto Tei, Hideaki Miyake, and Masato Fujisawa Hiromoto TeiHiromoto Tei More articles by this author , Hideaki MiyakeHideaki Miyake More articles by this author , and Masato FujisawaMasato Fujisawa More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2073AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES CD44 has been shown to play important roles in the progression of malignant tumors, including prostate cancer, by generating variant isoform through alternative splicing of variant exons, and its expression potentially influences stem cell behavior of cancer cells by a wide range of mechanisms. However, few data are available concerning the impact of CD44 expression on the prognosis of patients with prostate cancer, particularly those with localized disease. The objective of this study was to retrospectively evaluate the expression of CD44 standard form (CD44s) and two major variant exons (CD44v6 and CD44v10) in localized prostate cancer to determine the prognostic significance of these markers following radical prostatectomy. METHODS Expression levels of CD44s, CD44v6, and CD44v10 in radical prostatectomy specimens from 160 patients with clinically localized prostate cancer were evaluated by immunohistochemical staining. These findings were analyzed according to several clinicopathological outcomes, including biochemical recurrence (BR) which was defined as PSA of 0.2 ng/ml or greater on two consecutive measurements. In this series, irrespective of the pathological findings suggesting a poor prognosis, none of the patients were treated with any adjuvant therapies until their serum PSA values reached 0.4 ng/ml or greater. RESULTS Of these 3 markers, expression level of CD44v6 was closely associated with several conventional prognostic factors. Univariate analysis identified eight factors, including PSA level, Gleason score, extraprostatic extension, surgical margin status, lymphatic invasion, microvascular invasion, seminal vesicle invasion and CD44v6 expression, as significant risk factors for BR. Of these significant factors, PSA level, surgical margin status and CD44v6 expression were appeared to be independently associated with BR on multivariate analysis. There were significant differences in BR-free survival according to positive numbers of these 3 independent factors; that is, BR occurred in none of 42 patients who were negative for risk factors (0%), 9 of 54 positive for one risk factor (16.7%) and 31 of 64 positive for two or three risk factors (48.4%). CONCLUSIONS These findings suggest that the combined evaluation of the expression levels of CD44 variant exons, particularly CD44v6, in radical prostatectomy specimens with conventional prognostic parameters would contribute to the accurate prediction of BR following radical prostatectomy for clinically localized prostate cancer. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e684 Peer Review Report Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hiromoto Tei More articles by this author Hideaki Miyake More articles by this author Masato Fujisawa More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...